Investing.com -- RegenLab USA, Inc., a Swiss-founded regenerative medicine developer specializing in point-of-care cell processing devices, has filed a Form S-1 registration statement with the SEC to ...
智通财经APP获悉，专注于组织修复等再生医学用途的医疗器械公司RegenLab USA于周二公布了IPO条款。这家总部位于新泽西州泽西市的公司计划以每股6至8美元的价格发行250万股股票，募资1800万美元。按拟议发行价区间中值计算，RegenLab USA完全稀释后市值将达到1.57亿美元。 RegenLab开发并生产一次性器械，可在诊疗现场制备自体富血小板血浆(PRP)，既可单独使用，也可与透 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results